Study identifier:D516AC00001
ClinicalTrials.gov identifier:NCT04351555
EudraCT identifier:2020-000058-89
CTIS identifier:2022-502606-33-00
A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Phase 3
No
Osimertinib, Cisplatin, Carboplatin, Placebo, Pemetrexed
All
358
Interventional
18 Years - 100 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Feb 2025 by AstraZeneca
AstraZeneca
-
This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer
Location
Location
Kashiwa, Japan, 227-8577
Location
Hanoi, Vietnam, 100000
Location
Ho Chi Minh, Vietnam, 700000
Location
Ho Chi Minh, Vietnam, 70000
Location
Daegu, Republic of Korea, 41404
Location
Seoul, Republic of Korea, 08308
Location
Kazan, Russian Federation, 420029
Location
Chiang Mai, Thailand, 50200
Arms | Assigned Interventions |
---|---|
Placebo Comparator: Arm 1: Placebo with platinum-based chemotherapy Placebo plus investigator’s choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin) | Drug: Cisplatin Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles. Drug: Carboplatin Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles Drug: Placebo Oral Drug: Pemetrexed Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles |
Experimental: Arm 2: Osimertinib with platinum-based chemotherapy Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator) plus investigator’s choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin) | Drug: Osimertinib Oral Other Name: AZD9291; TAGRISSO Drug: Cisplatin Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles. Drug: Carboplatin Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles Drug: Pemetrexed Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles |
Experimental: Arm 3: Osimertinib monotherapy Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator) | Drug: Osimertinib Oral Other Name: AZD9291; TAGRISSO |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.